Faculty, Staff and Student Publications
Publication Date
10-1-2022
Journal
Cancer Science
Abstract
Study 309/KEYNOTE-775 is a phase 3 open-label, randomized trial of lenvatinib plus pembrolizumab versus treatment of physician's choice (TPC) in patients with advanced endometrial cancer with progression after platinum-based therapy. Primary endpoints of superiority for lenvatinib plus pembrolizumab were met for progression-free survival (PFS) and overall survival (OS) in all-comers (ie, regardless of mismatch repair [MMR] status) and patients with MMR proficiency (pMMR). We present results for the Japanese subset. Patients were randomized to oral lenvatinib 20 mg/day plus intravenous pembrolizumab 200 mg every 3 weeks (Q3W; up to 35 cycles of pembrolizumab) or TPC (intravenous doxorubicin 60 mg/m
Keywords
Antibodies, Monoclonal, Humanized, Antineoplastic Combined Chemotherapy Protocols, Doxorubicin, Endometrial Neoplasms, Female, Humans, Japan, Paclitaxel, Phenylurea Compounds, Quinolines
DOI
10.1111/cas.15436
PMID
35612971
PMCID
PMC9530883
PubMedCentral® Posted Date
July 2022
PubMedCentral® Full Text Version
Post-print
Published Open-Access
yes
Included in
Bioinformatics Commons, Biomedical Informatics Commons, Medical Sciences Commons, Obstetrics and Gynecology Commons, Oncology Commons, Women's Health Commons
Comments
Supplementary Material
Data Availability Statement
PMID: 35612971